Female hormone optimization starts with knowing which hormones change, when they change, and what options exist. This review covers the questions our clinical team most commonly sees from women evaluating hormone support through asynchronous telehealth.
The answers below reflect current research and a pharmacist-reviewed clinical perspective. They're educational—not a substitute for individualized evaluation. If something resonates with your health picture, a licensed provider's asynchronous review of your full history is the appropriate next step.
What Hormones Matter Most for Women's Health and Longevity?
The major steroid hormones affecting women's health and aging are estrogen (primarily estradiol), progesterone, testosterone, and DHEA (dehydroepiandrosterone, a precursor to both estrogen and testosterone). Thyroid hormones (T3 and T4), cortisol, insulin, and GH (growth hormone) also matter significantly—but estrogen, progesterone, and testosterone form the core of what most women mean when they discuss female hormone health.
Estradiol (E2) is the dominant form of estrogen in premenopausal women and the primary driver of bone density maintenance, cardiovascular protection, skin integrity, mood regulation, and vaginal/urogenital health. It also modulates cognition, sleep, and libido.
Progesterone counterbalances estrogen in the uterine lining (critical for anyone with a uterus who uses estrogen therapy), supports sleep, and has anti-anxiety effects through its metabolite allopregnanolone.
Testosterone is produced in smaller amounts in women than men, but plays a meaningful role in libido, lean muscle maintenance, energy, and mood. It often declines before estrogen does in perimenopause.
DHEA declines steadily from peak levels in the 20s onward. It serves as a precursor to both estrogen and testosterone in peripheral tissues and has been studied in the context of aging, energy, and sexual health. The DHEA research overview at TelosRX covers the evidence in detail.
How Do Estrogen and Progesterone Change With Age?
The transition typically begins in perimenopause—often in the mid-to-late 40s, sometimes earlier. Perimenopause is defined by irregular cycles and hormonal variability, not the absence of periods. It can last 2–12 years before menopause (12 consecutive months without a period) is confirmed.
During perimenopause, estradiol becomes erratic—sometimes spiking, sometimes dropping. Progesterone tends to fall first. This progesterone-estrogen imbalance is often what drives early perimenopausal symptoms: disrupted sleep, mood changes, breast tenderness, and cycle irregularity.
After menopause, estradiol settles at a consistently low level (typically <30 pg/mL versus 50–400 pg/mL during the reproductive years). Progesterone also drops sharply. Testosterone declines more gradually over the 40s–50s rather than acutely at menopause.
Post-menopausal hormonal changes are associated with accelerated bone loss, lipid profile shifts (higher LDL, lower HDL), changes in body composition, and increased cardiovascular risk. These are measurable, biologically meaningful changes—not just symptoms to manage.
What Are Common Signs of Hormonal Imbalance in Women?
Symptoms aren't always specific to one hormone. Overlap is common. But here are patterns worth tracking:
- Low estrogen: hot flashes, night sweats, vaginal dryness, disrupted sleep, joint pain, difficulty concentrating, mood changes, low libido
- Low progesterone (relative to estrogen): anxiety, poor sleep, PMS-like symptoms, irregular cycles, breast tenderness
- Low testosterone in women: low libido, fatigue, reduced motivation, difficulty maintaining muscle, mood flatness
- Low DHEA: fatigue, low energy, reduced sense of vitality, dry skin, poor stress tolerance
These symptoms overlap significantly with thyroid dysfunction, sleep disorders, and metabolic conditions. A lab panel—not symptoms alone—is needed to identify what's actually driving the picture. Symptom tracking is the starting point; labs confirm or rule out hormonal causes.
What Lab Tests Should Women Request for Hormone Evaluation?
| Hormone | Lab Test | Typical Range (Premenopause) | Typical Range (Postmenopause) |
|---|---|---|---|
| Estrogen (primary) | Estradiol (E2) | ~50–400 pg/mL (cycle-dependent) | <30 pg/mL |
| Progesterone | Serum progesterone | <1 ng/mL (follicular), 5–20 ng/mL (luteal) | <0.5 ng/mL |
| Testosterone (total) | Total testosterone | ~15–70 ng/dL | ~10–50 ng/dL (varies) |
| Testosterone (free) | Free testosterone (calc. or direct) | Variable; reference range lab-specific | Lower than premenopause |
| DHEA-sulfate | DHEAS | ~65–380 µg/dL (age-dependent) | Lower; declines with age |
| FSH | Follicle-stimulating hormone | <10 mIU/mL | >30 mIU/mL (confirms menopause) |
| Thyroid | TSH, Free T3, Free T4 | TSH ~0.4–4.0 mIU/L | Same reference range |
A full panel also typically includes a metabolic panel, CBC, and—depending on clinical history—IGF-1 (if GH axis concerns are present) and lipids. Your licensed provider determines which labs are appropriate based on your history and goals.
What Is Hormone Replacement Therapy (HRT) and What Does It Typically Involve?
Hormone replacement therapy (HRT)—sometimes called menopause hormone therapy (MHT)—involves supplementing hormones that have declined to restore or support physiological levels. Most commonly, this means estrogen (with or without progesterone).
For women with a uterus, estrogen is typically combined with progesterone (or a synthetic progestin) to protect the uterine lining. For women without a uterus, estrogen alone may be prescribed.
Delivery methods include transdermal patches, gels, creams, vaginal rings, oral pills, and pellet implants. Transdermal delivery is increasingly preferred because it avoids first-pass liver metabolism, which may reduce certain risks associated with oral estrogen (particularly VTE risk).
Low-dose testosterone may also be added for women with documented low testosterone and related symptoms, subject to individual clinical review. This is typically not FDA-approved for women (testosterone is approved only for men), and compounded testosterone for women is not FDA-approved.
Any hormone therapy, including compounded formulations, requires a provider-issued prescription and individualized clinical evaluation. Subject to medical approval by a licensed provider.
What Does Research Show About HRT and Long-Term Health for Women?
The research picture has shifted substantially since the 2002 Women's Health Initiative (WHI) results were initially reported. The WHI used oral conjugated equine estrogen plus medroxyprogesterone acetate—and found increased risk of breast cancer, cardiovascular events, and stroke in the treated group. These findings changed prescribing patterns dramatically.
What's become clearer since: the WHI findings applied most strongly to older women (average age 63) who started HRT well after menopause—not to women in perimenopause or early postmenopause. The “timing hypothesis” in hormone research now holds that HRT initiated within 10 years of menopause or before age 60 may carry a more favorable risk-benefit profile.
Research on bioidentical hormones (chemically identical to endogenous hormones—estradiol, progesterone) vs. synthetic formulations continues. The body of evidence for transdermal estradiol plus micronized progesterone—the most commonly used combination in current practice—is generally more favorable than the WHI's older oral conjugated estrogen formulations.
A 2025 review on therapeutic peptides and aging (PMC13095733) notes that hormonal decline is a central hallmark of aging—and that targeted interventions addressing hormonal decline are an active frontier in gerontological medicine. Research on DHEA specifically shows that DHEAS levels correlate with epigenetic age markers, suggesting hormonal support may have relevance beyond symptom management (PMC12357812).
Interested in how TelosRX approaches hormone evaluation? The TRT evaluation guide covers how provider-reviewed hormone protocols are structured at TelosRX.
Can Peptides Support Female Hormone Balance?
Some peptides interact with the hormonal axis and are studied in the context of female health—though this is an area where the evidence is still developing. A few examples:
- Kisspeptin — a neuropeptide that regulates GnRH (gonadotropin-releasing hormone) pulsatility, which in turn drives LH and FSH release and ultimately estrogen and progesterone production. Research in women is early-stage but active. Not FDA-approved. The kisspeptin research overview covers what's currently known.
- DSIP (Delta Sleep-Inducing Peptide) — studied in the context of sleep regulation; relevant to perimenopausal women whose sleep disruption is driven by hormonal changes.
- GH secretagogues (sermorelin, CJC-1295) — GH declines with age and in parallel with sex hormone changes. GH support is relevant to body composition and energy in some women, subject to IGF-1 evaluation and provider review.
No peptide is FDA-approved for the purpose of female hormone optimization. All are compounded and require provider evaluation and a provider-issued prescription. Subject to medical approval by a licensed provider.
How Does an Asynchronous Telehealth Evaluation Work for Hormone Concerns?
TelosRX operates as an online-first, asynchronous telehealth service. You don't need to schedule a real-time appointment. The process looks like this:
- Complete an intake form covering your health history, current symptoms, medications, and relevant labs if available
- A licensed provider reviews your information asynchronously—on their schedule, not yours
- If approved, a provider-issued prescription is generated and coordinated through the pharmacy
- Follow-up questions and protocol adjustments happen through the same asynchronous platform
This model works for women who need thoughtful clinical review but don't want to wait weeks for an in-person appointment. Approval is subject to evaluation by a licensed provider and is not guaranteed. Not every patient is a candidate for hormone therapy.
Start your evaluation at TelosRX—subject to provider review and approval.
Frequently Asked Questions
Is compounded bioidentical HRT safe?
Compounded bioidentical hormones are not FDA-approved, and the FDA has expressed concerns about unsubstantiated safety and efficacy claims from some compounding pharmacies. That said, many licensed providers use compounded estradiol and progesterone for individualized dosing. Your provider evaluates the full clinical picture—including risks and benefits—before prescribing. Subject to medical approval by a licensed provider.
At what age should women start thinking about hormone evaluation?
There's no fixed age. Perimenopause can begin in the early 40s or even late 30s. If you're experiencing symptoms consistent with hormonal change—irregular cycles, sleep disruption, mood shifts, hot flashes—a hormone panel is reasonable regardless of age. Lab results plus symptom history inform the clinical picture more than age alone.
Can women use testosterone therapy?
Testosterone therapy for women is not FDA-approved (it's approved only for men). However, compounded low-dose testosterone is used off-label in clinical practice for women with documented low testosterone and related symptoms, subject to provider evaluation and a provider-issued prescription. Not every provider or practice offers this; individual review is required.
What is estrogen dominance, and is it real?
Estrogen dominance refers to a relative excess of estrogen compared to progesterone—either from too much estrogen, too little progesterone, or both. It's a clinical concept used in functional and integrative medicine. Whether it accurately describes a distinct hormonal state versus simply low progesterone is debated. Lab values (estradiol-to-progesterone ratio in the luteal phase) can help clarify the picture.
Does HRT increase breast cancer risk?
The relationship depends heavily on the type of hormone used, duration, and individual risk factors. The original WHI data showed increased risk with oral conjugated estrogen plus medroxyprogesterone acetate. More recent analyses of transdermal estradiol plus micronized progesterone suggest a more favorable profile. Your provider reviews your personal and family history as part of the benefit-risk evaluation before prescribing.
How does menopause affect cardiovascular risk?
Estrogen has cardioprotective effects: it supports HDL-cholesterol levels, vascular tone, and anti-inflammatory signaling. After menopause, LDL typically rises and HDL may fall. Cardiovascular risk increases. Whether HRT initiated close to menopause can preserve some of this cardioprotection is an active area of research—the timing hypothesis remains an important focus in women's health research.
TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.
Start your private evaluation at TelosRX.